pS2 Negativity in Postmenopausal Women with ER + PgR + Infiltrating Ductal Breast Carcinoma is Associated with Reduced Hormone Dependence and Increased Proliferation and Aneuploidy of the Tumors

Brown A.M.C. , Jeltsch J.M. , Roberts M. , Chambon P. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci USA 1984; 81: 6344–8.

Ribeiras S. , Tomassetto C. , Rio M.C. The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochim Biophys Acta 1998; 1378: F61–77.

Rio M.C. , Bellocq J.P. , Gairad B. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci USA 1987; 84: 9243–7.

Gion M. , Mione R. , Pappagallo G.L. pS2 in breast cancer – alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Br J Cancer 1993; 68: 374–9.

Poulsom R. , Hanby A.M. , Lalani E.N. , Hauser F. , Hoffmann W. , Stamp G.W. Intestinal trefoil factor (TFF3) and pS2 (TFF1), but not spasmolytic polypeptide (TFF2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol 1997; 183: 30–8.

Ruibal A. , Fernández Llana B. , Alba A. , Nuñez M.I. , Martínez M.I. , Allende M.T. Cyfra 21.1 cytosolic levels in breast diseases. Correlation with other clinical and biological parameters. Int J Biol Markers 1996; 11: 90–2.

Westley B.R. , May F.E.B. Oestrogen regulates cathepsin D mRNA levels in oestrogen responsive human breast cancer cells. Nucleic Acid Res 1987; 15: 3773–86.

Suarez Cueva J.M. Cytosolic hyaluronic acid behaviour in breast diseases. Correlation with other clinical and biological parameters. Doctoral thesis, Universidad de Valladolid, 1997.

Rella C. , Coviello M. , Quaranta M. , Paradiso A. Tissuetype plasminogen activator as marker of functional steroid receptors in human breast cancer. Thromb Res 1993; 64: 209–20.

Jansen R.L.H. , Hupperets PSGJ , Arends J.W. pS2 is an independent prognostic factor for post-relapse survival in primay breast cancer. Anticancer Res 1998; 18: 577–82.

Shankey T.V. , Ravinovitch P.S. , Bruce B. Guidelines for the implementation of clinical DNA cytometry. Breast Cancer Res Treat 1993; 28: 61–8.